Inhibition of tumor growth by U0126 is associated with induction of interferon-γ production

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages 771-783

  Ma, Xingzhe ^a   Wang, Qixue ^a   Liu, Ying ^a   Chen, Yuanli ^a   Zhang, Ling ^a   Jiang, Meixiu ^a   Li, Xiaoju ^a   Xiang, Rong ^a   Miao, Robert Q ^b   Duan, Yajun ^a   Han, Jihong ^a  

^a NANKAI UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Carcinogens; ERK1 2; IFN ; LLC1; LXR; MEK1 2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GAMMA INTERFERON; KI 67 ANTIGEN; LIVER X RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; SMALL INTERFERING RNA; 1,3 BUTADIENE DERIVATIVE; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NITRILE; ORPHAN NUCLEAR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; GENE TRANSLOCATION; LEWIS CARCINOMA; LUNG; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR FREE SURVIVAL; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CELL LINE; CELL NUCLEUS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; BUTADIENES; CARCINOMA, LEWIS LUNG; CELL LINE; CELL NUCLEUS; FEMALE; GENE EXPRESSION; INTERFERON-GAMMA; LUNG; MAP KINASE KINASE KINASES; MICE, INBRED C57BL; NITRILES; ORPHAN NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918824827     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29038     Document Type: Article

References (43)

1. Maher SG, Romero-Weaver AL, Scarzello AJ, et al. Interferon: Cellular executioner or white knight? Curr Med Chem 2007;14:1279-89
2. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007;96:41-101
3. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon- gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89
4. Munder M, Mallo M, Eichmann K, et al. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med 1998;187:2103-8
5. Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Ann N Y Acad Sci. 2009; 1182:69-79
6. Le J, Prensky W, Yip YK, et al. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J Immunol 1983;131:2821-6
7. Pace JL, Russell SW, Torres BA, et al. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 1983;130:2011-3
8. Nathan CF, Murray HW, Wiebe ME, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-89
9. Keller R, Joller P, Keist R, et al. Modulation of major histocompatibility complex (MHC) expression by interferons and microbial agents. Independent regulation of MHC class II expression and induction of tumoricidal activity in bone marrow-derived mononuclear phagocytes. Scand J Immunol 1988;28:113-21
10. Chomarat P, RissoanMC, Banchereau J, et al. Interferon gamma inhibits interleukin 10 production by monocytes. J ExpMed 1993;177:523-7
11. Collart MA, Belin D, Vassalli JD, et al. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by shortlived repressors. J Exp Med 1986;164:2113-8
12. Donnelly RP, Fenton MJ, Finbloom DS, et al. Differential regulation of IL-1 production in human monocytes by IFN-gamma and IL-4. J Immunol 1990;145:569-75
13. Fantuzzi L, Gessani S, Borghi P, et al. Induction of interleukin-12 (IL-12) by recombinant glycoprotein gp120 of human immunodeficiency virus type 1 in human monocytes/macrophages: Requirement of gamma interferon for IL-12 secretion. J Virol 1996;70:4121-4
14. Gusella GL, Musso T, Bosco MC, et al. IL-2 upregulates but IFN-gamma suppresses IL-8 expression in human monocytes. J Immunol 1993;151: 2725-32
15. Chen Z, Gibson TB, Robinson F, et al. MAP kinases. Chem Rev 2001;101:2449-76
16. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47
17. Zhou X, Yin Z, Guo X, et al. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem 2010;285:6316-26
18. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocrine Rev 2001;22:153-83
19. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310
20. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010;3:8
21. Chapman MS, Miner JN. Novel mitogenactivated protein kinase kinase inhibitors. Expert Opin Invest Drugs 2011;20:209-20
22. Wang Q, Ma X, Chen Y, et al. Identification of interferon-gamma as a new molecular target of liver X receptor. Biochem J 2014;459:345-54
23. Chen Y, Duan Y, Kang Y, et al. Activation of liver X receptor induces macrophage interleukin- 5 expression. J Biol Chem 2012;287:43340-50
24. Meloche S, Pouyssegur J. The ERK1/2 mitogenactivated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 2007;26:3227-39
25. Scholl FA, Dumesic PA, Barragan DI, et al. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell 2007;12:615-29
26. Chambard JC, Lefloch R, Pouyssegur J, et al. ERK implication in cell cycle regulation. Biochim Biophys Acta 2007;1773:1299-310
27. Yang JY, Zong CS, XiaW, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2- mediated degradation. Nat Cell Biol 2008;10:138-48
28. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308
29. Sebolt-Leopold JS,Dudley DT,Herrera R, et al. Blockade of theMAP kinase pathway suppresses growth of colon tumors in vivo. NatMed 1999;5:810-6
30. Pages G, Guerin S, Grall D, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999;286:1374-7
31. Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci 2000;5:D479-87
32. Urashima M, Teoh G, Chauhan D, et al. Interleukin- 6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997;90:279-89
33. Marth C, Windbichler GH, Hausmaninger H, et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: Results of a phase I/II study. Int J Gynecol Cancer 2006;16:1522-8
34. Alberts DS, Marth C, Alvarez RD, et al. GRACES Clinical Trial Consortium. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progressionfree survival. Gynecol Oncol 2008;109:174-81
35. Giannopoulos A, Constantinides C, Fokaeas E, et al. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res 2003;9:5550-8
36. Tamura K, Makino S, Araki Y, et al. Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 1987;59:1059-62
37. Song JH, Wang CX, Song DK, et al. Interferon gamma induces neurite outgrowth by upregulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem 2005;280:12896-901
38. Burova EB, Smirnova IS, Gonchar IV, et al. Inhibition of the EGF receptor and ERK1/2 signaling pathways rescues the human epidermoid carcinoma A431 cells from IFNgamma-induced apoptosis. Cell Cycle 2011;10:2197-205
39. Gough DJ, Sabapathy K, Ko EY, et al. A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem 2007;282:938-46
40. Zhou B, He Y, Zhang X, et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci USA 2010;107:4573-8
41. Lombardi A, Cantini G, Piscitelli E, et al. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:718-24
42. Nguyen VA, Chen J, Hong F, et al. Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: Differential regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochem J 2000;349: 427-34
43. Töröcsik D, Baráth M, Benko S, et al. Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli. J Immunol 2010; 184:5456-65.